Identification of ABCC5 Among ATP-Binding Cassette Transporter Family as a New Biomarker for Hepatocellular Carcinoma Based on Bioinformatics Analysis
Yuting Qiu,Haobo Li,Jiaheng Xie,Xinwei Qiao,Jing Wu
DOI: https://doi.org/10.2147/IJGM.S333904
IF: 2.145
2021-10-27
International Journal of General Medicine
Abstract:Yuting Qiu, 1, &ast Haobo Li, 2, &ast Jiaheng Xie, 3 Xinwei Qiao, 1 Jing Wu 1 1 Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Centre for Digestive Diseases, Beijing, 100050, People's Republic of China; 2 Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100029, People's Republic of China; 3 Department of Burn and Plastic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xinwei Qiao; Jing Wu Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Centre for Digestive Diseases, No. 95, Yongan Road, Xicheng District, Beijing, 100050, People's Republic of China Tel +86-15010573490 ; +86-13701134610 Fax +86-10-63926370 Email ; Purpose: Liver cancer is the fifth most common type of cancer worldwide, and the ATP-binding cassette (ABC) transporter family has been widely accepted as a cause of multidrug resistance. This study was conducted to explore the potential value and mechanisms of the ABC transporter gene family in the liver hepatocellular carcinoma (LIHC). Materials and Methods: Data were collected from different public databases. UALCAN, ONCOMINE, and GEPIA were used to retrieve a selection of differently expressed and pathological stage-related genes among the ABC family. Principal component analysis (PCA) was utilized for grouping, and its prognostic value was evaluated by univariate and multivariate Cox analyses. The co-expression pattern was constructed with UALCAN, and the functional analyses were carried out with DAVID. The correlation between the biomarker and immune infiltration, genetic alteration frequency, and drug sensitivity were explored with TIMER, cBioPortal, GDSC and CTRP, respectively. Finally, tSNE algorithm was used to explore the distribution of ABCC5 expressed cells. Results: Among the ABC transporter family members, ABCC5 was differently expressed and strongly related to the pathological stage of LIHC. PCA divided patients of LIHC into two groups, and Cox analyses demonstrated that ABCC5 was an independent risk factor of LIHC. Functional analyses indicated that the genes were enriched in the pathways of transmembrane transporter, ATPase activity, and bile secretion. ABCC5 is also associated with immune infiltration of cells like macrophages, neutrophils, and dendritic cells. The genetic alteration frequency of ABCC5 confirmed its potential value in LIHC. In addition, several drugs were explored and found to be relevant to LIHC. The t-SNE showed that expression of ABCC5 was most concentrated in macrophages, followed by hepatocytes. Conclusion: ABCC5 may facilitate LIHC progression through different mechanisms and be a potential biomarker and target for diagnosis, prognosis, and therapy of LIHC. Keywords: LIHC, bioinformatics analysis, ATP-binding cassette transporter family, ABCC5 Liver cancer is the fifth most common type of cancer worldwide. According to statistics, the incidence of liver cancer accounted for 4.7% of cancers in 2018, while the number of deaths caused by liver cancer accounted for 8.2%, ranking it the fourth leading cause of cancer-related mortality worldwide. 1 Liver cancer tends to occur in elderly males with a male-to-female incidence ratio of approximately 2–2.5:1. Histopathology subtyping has shown that liver hepatocellular carcinoma (LIHC) represents about 90% of primary hepatic carcinomas. 2 As a result, LIHC is a serious and challenging global health problem. The major causes of LIHC include hepatitis C or B, alcoholic and non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome (MS), which is a pathological cluster of metabolic disorders that may also contribute to LIHC. 3,4 One of the reasons for its high mortality is the difficulty in detecting LIHC in an early stage. Currently, the treatment for LIHC consists of radical liver resection, liver transplantation, transcatheter arterial chemoembolization, radiofrequency ablation, radioembolization, and tyrosine-kinase inhibitors. 4 Despite the great amount of attention for biomarkers, no effective new biomarkers for diagnosis and surveillance of LIHC have been discovered. The recommended biomarkers for clinical usage such as Alpha-Fetoprotein (AFP), Alpha-Fetoprotein Lens Culinaris Agglutinin-3 (AFP-L3), and Des-γ-carboxy prothrombin (DFP) were i -Abstract Truncated-
medicine, general & internal